Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far
Anne Clavreul,1,2 Milad Pourbaghi-Masouleh,2,3 Emilie Roger,4 Philippe Menei1,2 1Department of Neurosurgery, CHU, Angers, France; 2CRCINA, INSERM, University of Nantes, University of Angers, Angers, France; 3Division of Drug Delivery and Tissue Engineering, School of Pharmacy, University o...
Guardado en:
Autores principales: | Clavreul A, Pourbaghi-Masouleh M, Roger E, Menei P |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0a2d800fa252474da15c67fff80cae46 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Composition of Algerian Propolis, Plant Origin, and Its Antiangiogenic Activity In Vitro
por: Takahiro Hosoya, et al.
Publicado: (2021) -
Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies
por: Hui Tian, et al.
Publicado: (2021) -
Antiangiogenic therapy for breast cancer with triple negative phenotype
por: Inna P. Ganshina, et al.
Publicado: (2021) -
A Simple Preoperative Blood Count to Stratify Prognosis in Isocitrate Dehydrogenase-Wildtype Glioblastoma Patients Treated with Radiotherapy plus Concomitant and Adjuvant Temozolomide
por: Anne Clavreul, et al.
Publicado: (2021) -
Exosomes: Novel Bio-Inspired Nanocarriers for Efficient Targeting of Glioblastoma Tumor Cells
por: V Taghdiri Nooshabadi, et al.
Publicado: (2021)